Olaparib in ovarian cancer with BRCA mutation

被引：5

作者：

Pujade-Lauraine, Eric ^{[1
]}

Combe, Pierre ^{[2
]}

机构：

[1] GH Paris Ctr, Ctr Canc Femme & Rech Clin, F-75181 Paris 04, France

[2] Hop Europeen Georges Pompidou, Serv Oncol Med, F-75015 Paris, France

来源：

BULLETIN DU CANCER | 2015年 / 102卷 / 06期

关键词：

BRCA; Ovarian cancer; Olaparib; PARP;

D O I：

10.1016/S0007-4551(15)31221-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

With 4500 new cases and 3200 death each year, ovarian cancer is the first cause of mortality for gynecological cancer in France. Without any efficient screening, it is usually diagnosed around the age of 60 years at an advanced stage. The emergence of olaparib, a new targeted therapy, represents a major opportunity.

引用

页码：S82 / S84

页数：3

共 50 条

[1] Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation
Stewart, James
George, Angela
Banerjee, Susana
EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (10) : 947 - 958
[2] Olaparib for BRCA-mutated advanced ovarian cancer
de Lartigue, Jane
JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2015, 13 (06): : 206 - 208
[3] Olaparib Maintenance Therapy in BRCA-positive Ovarian Cancer
Lorenz, Judith
GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (03)
[4] Olaparib for the treatment of BRCA-mutated advanced ovarian cancer
Munroe, Marklie
Kolesar, Jill
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2016, 73 (14) : 1037 - 1041
[5] Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, Mark
Im, Seock-Ah
Senkus, Elzbieta
Xu, Binghe
Domchek, Susan M.
Masuda, Norikazu
Delaloge, Suzette
Li, Wei
Tung, Nadine
Armstrong, Anne
Wu, Wenting
Goessl, Carsten
Runswick, Sarah
Conte, Pierfranco
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (06): : 523 - 533
[6] BEHAVIOR OF BRCA MUTATION IN OVARIAN CANCER
Climent Mari, M. T.
Sala de la Concepcion, A.
Marti Cardona, M. D.
Barahona Orpinell, M.
Rovira Montane, J.
Pla Farnos, M. J.
Ponce Sebastia, J.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1469 - 1469
[7] Cost-effectiveness analysis of olaparib maintenance therapy for BRCA mutation ovarian cancer in the public sector in Malaysia
Yong, Chee Meng
Yehgambaram, Prathepamalar A. P.
Lee, Shaun Wen Huey
PLOS ONE, 2024, 19 (02):
[8] New drug approval: Olaparib - pancreatic cancer with BRCA germline mutation
Hilmi, Marc
Neuzillet, Cindy
BULLETIN DU CANCER, 2020, 107 (10) : 961 - 962
[9] The efficacy of olaparib in BRCA-mutated ovarian cancer: a systematic review
Wibisono, M. G.
Wibisono, M. H.
Sabran, M. Z.
Wibisono, J.
ANNALS OF ONCOLOGY, 2024, 35 : S1403 - S1404
[10] Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease
Bangham, Madeleine
Goldstein, Robert
Walton, Henry
Ledermann, Jonathan A.
GYNECOLOGIC ONCOLOGY REPORTS, 2016, 18 : 22 - 24

← 1 2 3 4 5 →